Get the Stockscreener App
50.56
0.10%
0.05
After Hours:
50.56
Akero Therapeutics Inc stock is traded at $50.56, with a volume of 561.88K.
It is up +0.10% in the last 24 hours and down -8.14% over the past month.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
See More
Previous Close:
$50.51
Open:
$50.41
24h Volume:
561.88K
Relative Volume:
0.36
Market Cap:
$4.03B
Revenue:
-
Net Income/Loss:
$-269.44M
P/E Ratio:
-13.48
EPS:
-3.75
Net Cash Flow:
$-262.63M
1W Performance:
-2.92%
1M Performance:
-8.14%
6M Performance:
+93.12%
1Y Performance:
+78.53%
1-Day Range:
$49.61
$50.83
1-Week Range:
$49.61
$52.80
52-Week Range:
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Name
Akero Therapeutics Inc
Sector
Industry
Phone
650-487-6488
Address
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Compare AKRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
50.56 | 4.03B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-27-25 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-24 | Initiated | Citigroup | Buy |
| Apr-22-24 | Resumed | BofA Securities | Neutral |
| Sep-19-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-23 | Initiated | UBS | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-14-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Initiated | Guggenheim | Buy |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Jul-20-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-02-20 | Initiated | H.C. Wainwright | Buy |
| Feb-10-20 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Evercore ISI | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
| Jul-15-19 | Initiated | Jefferies | Buy |
| Jul-15-19 | Initiated | ROTH Capital | Buy |
View All
Akero Therapeutics Inc Stock (AKRO) Latest News
Is Akero Therapeutics Inc. a growth stock or a value stockUnlock expert trading strategies for growth - jammulinksnews.com
What makes Akero Therapeutics Inc. stock price move sharplyBuild wealth faster with expert stock picks - jammulinksnews.com
Jennison Associates LLC Invests $533,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Readystate Asset Management LP Acquires Shares of 100,500 Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Teachers Retirement System of The State of Kentucky Has $780,000 Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock Holdings Lowered by Kennondale Capital Management LLC - MarketBeat
What analysts say about Akero Therapeutics Inc. stockTremendous growth potential - PrintWeekIndia
Is Akero Therapeutics Inc. a good long term investmentFast-track wealth growth - PrintWeekIndia
What drives Akero Therapeutics Inc. stock priceHigh-margin investment plays - PrintWeekIndia
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by Bank of New York Mellon Corp - MarketBeat
AstraZeneca’s Anselamimab Misses Primary Endpoint in Amyloidosis Trials, Shows Promise in Subgroup - Insider Monkey
Is Akero Therapeutics Inc. stock a growth or value playFree Trend-Following Techniques - jammulinksnews.com
How to Take Advantage of moves in (AKRO) - news.stocktradersdaily.com
Edgestream Partners L.P. Acquires Shares of 6,947 Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics Inc. Stock Analysis and ForecastFastest-growing stock picks - Autocar Professional
5,565 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Bought by Xponance Inc. - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $529,500.00 in Stock - MarketBeat
257,025 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Purchased by Principal Financial Group Inc. - MarketBeat
Mirum Gains 35% in 3 Months: How Should You Play the Stock? - The Globe and Mail
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $82.50 Average Price Target from Analysts - MarketBeat
Emerald Advisers LLC Has $11.92 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
How Akero Therapeutics Inc. stock performs during market volatilityFree Stock Market Forecasting Tools - beatles.ru
Emerald Mutual Fund Advisers Trust Sells 145,145 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics Inc Stock (AKRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):